Equities review: Boeing Company, AT&T Inc., Baker Hughes, Campbell & Johnson & Johnson

The Boeing Company (NYSE:BA) stock gained 0.75% to $74.24 in the morning hour after The Boeing Company and Air Lease Corporation announced a firm order for 60 737 MAX 8 and 15 737 MAX 9 airplanes, with reconfirmation rights for 25 additional 737 MAXs. The order with a list-price value of $7.2 billion. Air Lease Corporation has ordered a total of 170 airplanes from Boeing including 75 737 MAX, 78 Next-Generation 737-800s, five 777-300ERs (Extended Range) and 12 787-9 Dreamliners.

AT&T Inc. (NYSE:T) shares fell 0.25% to $35.35 in the early hour. Beginning July 15, the company will add unlimited texting to Canada, Mexico and 100 other countries to its $25 per month GoPhone prepaid rate plan, a feature previously only available on the $50 per month or $2 per day plans. AT&T is a premier communications holding company and one of the most honored companies in the world. Its subsidiaries and affiliates - AT&T operating companies - are the providers of AT&T services in the United States and around the world.

Baker Hughes Incorporated (NYSE:BHI) shares increased 0.30% to $40.40 in the morning hour after the company announced that the international rig count for June 2012 was 1,285 rigs. The June international rig count includes the addition of 79 rigs in Iraq. This is the first time Baker Hughes has included Iraq in its international rig count since 1990.

Campbell Soup Company (NYSE:CPB) stock fell 0.85% to $32.71 in the early hour after the company announced today that it has entered into an agreement to acquire Bolthouse Farms from a fund managed by Madison Dearborn Partners, LLC, a private equity firm, for $1.55 billion in cash. The acquisition of Bolthouse will provide Campbell with significant presence and a new platform for expansion in the rapidly growing, $12-billion market for packaged fresh foods.

Johnson & Johnson (NYSE:JNJ) stock increased 0.19% to $67.77 in the morning hour after Bayer and Johnson & Johnson's anti-blood-clotting pill, Xarelto, won priority review status from the U.S. Food and Drug Administration (FDA) for the treatment of deep vein thrombosis and pulmonary embolism. The priority review also includes the drug's use in the long-term prevention of venous thromboembolism in patients who have already suffered an attack.